Abstract
Background: Osteoporosis is the most common and widespread chronic skeletal metabolic disease in the world and can lead to catastrophic fractures. Therefore, it is important to look for factors that can be modified or controlled to prevent osteoporosis. Although serum Mg is believed to be associated with osteoporosis in many individuals, there are conflicting reports on the association between serum Mg and osteoporosis. Therefore, this meta-analyses aimed to explore the association between the concentration of serum Mg and osteoporosis as well as that between the concentration of serum Mg and osteopenia.
Methods: Articles were searched in PubMed. We also reviewed the reference lists of the relevant publications and reviews as of December 2019. Finally, 11 eligible studies involving 2,776 postmenopausal women were selected. We performed subgroup analysis, and publication bias was assessed.
Results: According to the forest plot analysis, postmenopausal women with osteoporosis had a lower concentration of serum Mg than normal controls [standardized mean difference (SMD) = −0.56, 95% confidence interval (CI) = −1.02 to −0.09]. However, this result was not applicable to those with osteopenia (SMD = −0.30, 95% CI = −0.69 to 0.09). The subgroup analysis by geographical location found a similar pattern in European postmenopausal women with osteoporosis (SMD = −0.73, 95% CI = −1.322 to −0.143), but not in Asian (SMD = −0.007, 95% CI = −0.381 to 0.394). The subgroup analysis by site of bone mineral density (BMD) showed the serum Mg concentration of postmenopausal women with osteoporosis (BMD of femur) was lower than in healthy controls (SMD = −0.44, 95% CI = −0.77 to −0.12), and BMD of the spine group had the same conclusion (SMD = −0.78, 95% CI = −1.36 to −0.19). Besides, the serum Mg concentration of postmenopausal women with osteoporosis was lower than that of the normal bone mass group in the studies those included more than 50 postmenopausal women with osteoporosis (SMD = −0.57, 95% CI = −1.04 to −0.11). We also found postmenopausal women under the age of 60 with osteoporosis had a lower concentration of serum Mg than the healthy controls (SMD = −0.61, 95% CI = −1.09 to −0.13).
Conclusion: Postmenopausal women with osteoporosis have a lower concentration of serum Mg. However, the association between the concentration of serum Mg and osteopenia needs further confirmation.
Introduction
Osteoporosis is defined as progressive systemic skeletal disease, characterized by low bone mass and microstructure deterioration of bone tissue, reduced bone mineral density (BMD) and bone strength that increase the risk of fracture (–). Meanwhile, osteopenia is a chronic skeletal metabolic disorder with a BMD lower than normal but not as low as that in osteoporosis, which usually increases in severity with age and is most common in postmenopausal women (, ). The endpoint of osteopenia is osteoporosis. The gold standard for the diagnosis of osteoporosis is using dual-energy X-ray absorptiometry to measure BMD in the lumbar spine and hips. The value of T-score can be divided into normal bone mass (T-score ≥ −1), osteopenia (−1> T-score > −2.5) and osteoporosis (T-score ≤ −2.5). A terrible consequence of osteoporosis is primarily the osteoporotic fracture. According to the statistics, the incidence of osteoporotic fractures in postmenopausal women is 40 percent or higher in Western Europe and the remaining lifetime probability was ~12%. In addition, the annual number of fragility fractures will rise 4.5 million in 2025 in the EU (). This means a high personal and social price to pay for osteoporosis.
In addition to the well-known risk factors (e.g., nutritional deficiency), there is increased interest in the role of trace elements and vitamin deficiencies associated with osteoporosis (). Current recommendations regarding nutrient factors for the prevention of osteoporosis are calcium, phosphorus, vitamin D, magnesium (Mg), and fluoride. Among these factors, Mg is the least reported in the literature. Mg deficiency can lead to osteoporosis mainly through the following mechanisms: (1) changing the mechanism of hydroxyapatite affects bone mineralization, and enhancing bone turnover by stimulating the function of osteoclasts; (2) destroying the homeostasis of calcium by affecting parathyroid hormone (PTH) and 1,25(OH)2-vitamin D, which could lead to hypocalcemia; (3) promoting inflammation, by inflammatory cytokines stimulating remodeling and osteopenia; (4) promoting endothelial dysfunction (). It has been confirmed in animal and human experiment models that Mg deficiency is associated with reduced osteoclastic and osteoblastic activity, osteopenia, and skeletal fragility (, ). In rat models with severely deficient Mg diets, impaired bone growth and exacerbation of loss of bone mass were observed (–). Micro-computed tomography revealed that the number of femoral trabecular bones are decreased, and the BMD subsided in distal metaphysis in the low Mg mice (). In vitro, osteoblasts proliferate rapidly in a dilution of one-fold concentration of Mg extract, indicating that the extract of high concentration of Mg can promote the proliferation/differentiation behavior of osteoblasts ().
Therefore, clarifying the association among the concentration of serum Mg, osteoporosis, and osteopenia can help in the formulation of clinical policy and guidelines. Therefore, this meta-analyses aimed to explore the association between the concentration of serum Mg and osteoporosis as well as that between the concentration of serum Mg and osteopenia.
Methods
Search Strategy
All articles that were indexed up to December 2019 and published in PubMed were searched. Literature searches were performed using free text words. The search keywords used were: “serum magnesium” OR “magnesium” AND “osteoporosis” AND “osteopenia.” Additionally, to find other publications, articles cited in the references of identified relevant articles were used. We included studies written in all languages.
Selection Criteria
The articles were independently selected and reviewed by three authors (DY, JJ, NW) who started by screening titles and abstracts according to the relevance of the topic. After reading the abstract, the full text was screened for appropriate studies to include in the meta-analysis. Eligible studies for inclusion were independently selected by two authors (JJ, NW). When it was not clear whether a study should be included or not, there was a discussion with the third author (DY) to establish a consensus.
The inclusion criteria for eligible studies were as follows: (1) studies involving human subjects, (2) observational studies, (3) studies focusing on the association between the concentration of serum Mg and osteoporosis or osteopenia, (4) studies included data on the concentration of serum Mg for patients with osteoporosis or osteopenia and healthy individuals, and (5) studies that did not characterize diseases and drug intake that might influence the concentration of serum Mg.
The exclusion criteria were as follows: (1) studies with animal subjects, (2) in vitro or laboratory studies, (3) reviews or case reports, (4) studies not providing exact data on the concentration of serum Mg, (5) studies with diseases or medications that may affect the concentration of serum Mg, and (6) studies with sample size <10.
Data Extraction and Quality Assessment
The two authors (DY, SY) used a standard form to extract data independently. The following information was extracted from each included study: the surname of the first author, year of publication, continent, the sample size, and data on the concentration of serum Mg in different groups (mean ± SD) (Table 1).
Table 1
| Name | Year | Design | Location | Osteoporosis' number | The level of serum Mg (Mean±SD) mg/dl | Age of subjects (years) | BMD instrument | Site of BMD | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Osteoporotic | Osteopenia | Healthy | ||||||||
| Reginster | 1989 | Case-control | European | 10 | 1.968 ± 0.144 | 2.088 ± 0.096 | ≥60 | Dual-photon absorptiometry | Thoracic spine, lumbar spine | |
| Ali | 2002 | Case-control | European | 70 | 2.699 ± 0.738 | 3.252 ± 0.623 | ≥60 | DEA | Spine, femur | |
| Berna | 2010 | Case-control | European | 25 | 2.07 ± 0.31 | 2.13 ± 0.42 | 2.28 ± 0.63 | <60 | DEA | L2–L4 spine |
| Chen | 2007 | Case-control | Asia | 113 | 1.776 ± 0.2928 | 1.771 ± 0.2904 | 1.785 ± 0.2376 | ≥60 | DEA | L1–L4 spine |
| Liu | 2009 | Case-control | Asia | 123 | 1.968 ± 0.252 | 1.912 ± 0.281 | 1.935 ± 0.221 | <60 | DEA | L1–L4 spine, Femoral neck, Ward's triangle, greater trochanter, and intertorch of femur |
| Mutlu | 2007 | Case-control | European | 40 | 1.7 ± 0.2 | 2.2 ± 0.2 | 2.7 ± 0.4 | <60 | DEA | Femoral neck |
| Bahtiri | 2015 | Case-control | European | 49 | 2.594 ± 0.2400 | 1.968 ± 0.2160 | 1.992 ± 0.2160 | ≥60 | DEA | Total hip, Femoral neck, L1–L4 spine |
| Mederle | 2018 | Case-control | European | 132 | 1.76 ± 0.06 | 2.14 ± 0.14 | ≥60 | DEA | Lumbar spine, femoral | |
| Wang | 2006 | Case-control | Asia | 77 | 2.184 ± 0.2640 | 2.112 ± 0.2160 | 2.088 ± 0.1920 | ≥60 | DEA | Spine, Femur neck |
| Razmandeh | 2014 | Case-control | Asia | 30 | 1.508 ± 0.489 | 1.980 ± 0.823 | ≥60 | DEA | L1–L4 spine, total femoral | |
| Okyay | 2013 (1) | Case-control | European | 142 | 0.86 ± 0.1 | 0.89 ± 0.1 | <60 | DEA | L1–L4 spine | |
| Okyay | 2013 (2) | Case-control | European | 71 | 0.84 ± 0.16 | 0.89 ± 0.17 | <60 | DEA | Total femoral | |
| Okyay | 2013 (3) | Case-control | European | 102 | 0.86 ± 0.18 | 0.89 ± 0.16 | <60 | DEA | Femoral neck | |
| Okyay | 2013 (4) | Case-control | European | 95 | 0.85 ± 0.1 | 0.94 ± 0.1 | ≥60 | DEA | L1–L4 spine | |
| Okyay | 2013 (5) | Case-control | European | 65 | 0.85 ± 0.14 | 0.91 ± 0.18 | ≥60 | DEA | Total femoral | |
| Okyay | 2013 (6) | Case-control | European | 87 | 0.86 ± 0.16 | 0.91 ± 0.17 | ≥60 | DEA | Femoral neck | |
Summary characteristics of studies and participants.
We used the Newcastle-Ottawa Scale to assess the qualities of all included studies and most of the included literature was rated above 7.
Statistical Analysis
We analyzed the extracted data from the included studies with a meta-analysis and present the results with a standardized mean difference (SMD) and 95% confidence intervals (CI). Chi-square (χ2) and I-square (I2) tests were used to test the heterogeneity between studies. When we used the χ2-test, we interpreted P < 0.10 to mean there was significant heterogeneity. When heterogeneity was detected, we used a DerSimonian-Laird random-effects model (). We used a Mantel-Haenszel fixed-effect model when no heterogeneity was detected.
I2 is believed to be a better measure of the consistency between trials in a meta-analysis, because it describes the percentage of total variation across studies that is due to heterogeneity rather than chance (). I2 values of 25, 50, and 75% were considered to be low, medium, and high heterogeneity ().
We performed subgroup analyses to identify associations between the concentration of serum Mg and the characteristics of studies to examine if this could explain heterogeneity. We used Begg's and Egger's regression tests and trim-and-fill funnel plots to assess publication bias (–).
Results
Literature Search
From the initial 475 articles, 455 were excluded after reading titles and abstracts because they did not meet the inclusion criteria. Twenty articles were included for full-text assessment, from which 9 were excluded from the sample studies: two did not have data on serum Mg; four mentioned osteoporosis, but their main target was osteoporotic fractures; two involved patients administered with drugs that improved the concentration of serum Mg|; one compared the concentration of serum Mg between osteoporosis and osteopenia. We included a total of 11 eligible papers, representing 2,776 postmenopausal women from 16 case-control studies [Figure 1; (, , –)]. Among them, according to the age and the location of measurement, Okyay's study () was divided into six part. In 10 of the studies, participants were over 60 years old. Except for Reginster's study (), other studies have measured BMD with DEA.
Figure 1
Meta-Analysis Results
The results of random-effects meta-analysis showed that women with osteoporosis had a lower concentration of serum Mg than the normal controls (SMD = −0.56, 95% CI = −1.02 to −0.09). The 16 sets of results showed a statistically significant heterogeneity (I2 = 96.6%, P < 0.001; Figure 2).
Figure 2
The random-effects forest plot for studies on the concentration of serum Mg in women with osteopenia vs. healthy controls had different results (SMD = −0.30, 95% CI = −0.69 to 0.09). This meant that in postmenopausal women, the relationship between serum magnesium concentration and osteopenia is not significant. The 16 sets of results showed a statistically significant heterogeneity (I2 = 86.3%, P < 0.001; Figure 2).
Results of Subgroup Analysis
The subgroup analyses showed that concentrations of serum Mg varied by geographical location. A lower concentration of serum Mg was found in European postmenopausal women with osteoporosis than in healthy controls (SMD = −0.73, 95% CI = −1.322 to −0.143), but not in Asian postmenopausal women with osteoporosis (SMD = −0.007, 95% CI = −0.381 to 0.394; Table 2).
Table 2
| Subgroups | No. of studies | SMD (95% CI) | I2 (%) | P |
|---|---|---|---|---|
| Geographical location | ||||
| Asia | 4 | −0.007 (−0.381 to 0.394) | 97.2% | 0.973 |
| European | 12 | −0.73 (−1.322 to −0.143) | 77.1% | 0.015 |
| Site of BMD | ||||
| Spine | 5 | −0.44 (−0.77 to −0.12) | 75.6% | 0.003 |
| Femur | 5 | −0.78 (−1.36 to −0.19) | 94.4% | 0 |
| Age | ||||
| ≥60 | 10 | −0.49 (−1.29 to 0.30) | 97.5% | 0 |
| <60 | 6 | −0.61 (−1.09 to −0.13) | 93.6% | 0 |
| Osteoporosis' number | ||||
| <50 | 5 | −0.53 (−2.33 to 1.28) | 97.6% | 0 |
| ≥50 | 11 | −0.57 (−1.04 to −0.11) | 96.4% | 0 |
Subgroup analysis to investigate the relationship between geographical location, sites of BMD, age, osteoporosis' number, and serum Mg.
In addition, we also conducted subgroup analysis based on the site of BMD, the included studies were divided into femur group (including total femoral, Femoral neck, Ward's triangle, greater trochanter, and intertorch of femur) and spine group (thoracic spine, lumbar spine) according to different sites. Studies that mention both the spine and the femur were excluded. The results showed the serum Mg concentration of postmenopausal women with osteoporosis (BMD of femur) was lower than in healthy controls (SMD = −0.44, 95% CI = −0.77 to −0.12), and BMD of the spine group had the same conclusion (SMD = −0.78, 95% CI = −1.36 to −0.19; Table 2).
We conducted a subgroup analysis based on the number of postmenopausal women with osteoporosis included in this study. The results showed that the serum Mg concentration of postmenopausal women with osteoporosis was lower than that of the normal bone mass group in the studies those included more than 50 postmenopausal women with osteoporosis (SMD = −0.57, 95% CI = −1.04 to −0.11). But in studies that included fewer than 50 postmenopausal osteoporosis, serum magnesium was not associated with osteoporosis (SMD = −0.53, 95% CI = −2.33 to 1.28; Table 2).
The results of the subgroup analysis by age showed that postmenopausal women under the age of 60 with osteoporosis had a lower concentration of serum Mg than the healthy controls (SMD = −0.61, 95% CI = −1.09 to −0.13). However, there was no correlation of serum Mg in postmenopausal women over 60 years old with osteoporosis and the healthy controls (SMD = −0.49, 95% CI = −1.29 to 0.30; Table 2).
Publication Bias
There was no statistically significant risk of publication bias between women with osteoporosis and healthy controls (Begg's test: P = 0.065; Egger's test: P = 0.337; Table 3). But the funnel plot was assessed to be asymmetric indicating the possibility of publication bias. To further assess the risk, the trim-and-fill method was used, which showed a statistically significant risk and an undervalued association between the concentration of serum Mg and osteoporosis in previous studies (Estimate = −0.5567, 95% CI = −1.022 to −0.911; Figure 3).
Table 3
| Group | P (Begg's test) | P (Egger's test) |
|---|---|---|
| Osteoporosis vs. normal | 0.065 | 0.337 |
| Osteopenia vs. normal | 0.024 | 0.096 |
Publication bias was determined by Begg's test and Egger's regression test.
Figure 3
However, there was a statistically significant risk of publication bias between women with osteopenia and healthy controls (Begg's test: P = 0.024; Egger's test: P = 0.096; Table 3). But after applying trim-and-fill, the results were not statistically significant (Estimate = −0.2994, 95% CI = −6.895 to 0.0906; Figure 3).
Discussion
Our random-effects meta-analysis revealed that postmenopausal women with osteoporosis had a lower concentration of serum Mg than the healthy controls; however, the concentration of serum Mg did not differ between those with osteopenia and healthy controls.
Mg has a close relationship with bone as bone stores comprise about 60% of total Mg. One-third of this skeletal Mg is found in cortical bone and serves as a reservoir for exchangeable Mg, which is beneficial to maintain the extracellular physiological concentrations of cations (). Accordingly, surface bone Mg increases with loading Mg (). Mg plays a fundamental role in the biological activation of ATP, which is the main source of energy for the cells (). Mg deficiency can lead to parathyroid hormone secretion disorders and can affect vitamin D and 1,25(OH)2-vitamin D synthesis. The latter three are important regulators of calcium and bone homeostasis. (, –). In Mg-deficient animals, newly formed apatite crystals are larger and better structured, which affects the stiffness of the bone (). Besides, Mg is mitogenic for osteoblasts. Low Mg inhibits osteoblast proliferation by increasing the release of nitric oxide through the up regulation of inducible nitric oxide synthase (), while it increases the number of osteoclasts by promoting osteoclastogenesis (). Taken together, maintaining Mg homeostasis can help maintain the homeostasis of osteoblasts and osteoclasts in order to prevent osteoporosis.
The regulation of serum magnesium mainly depends on intestinal absorption and renal excretion (). In the studies we included, those with diseases and drugs that affect serum Mg levels were excluded. Nevertheless, some chronic underlying diseases, such as renal insufficiency, chronic intestinal disease, or hyperthyroidism, may influence the concentration of serum Mg. This effect cannot be ruled out and may be an important source of heterogeneity in our results. In adults, serum Mg is generally independent of age and sex. The increase of serum Mg was only slightly higher in those very elderly women who were measured after intense short-lived active or vegetarian (). In general, Mg deficiency is mainly due to lower consumption, inadequate absorption, and/or increased excretion (). Although some possible confounders were controlled by inclusion criteria, dietary intake of Mg may have a significant effect on serum Mg. Considering that the diet structure will not change much in the short term within a region, we conducted a subgroup analysis based on the regional category. Our results showed a lower concentration of serum Mg was found in European postmenopausal women with osteoporosis than in healthy controls. This may be related to the insufficient intake of Mg in the European diet. While we analyzed the concentration of serum Mg between women with osteopenia and healthy controls, no correlation was found.
In order to further explore the heterogeneity between studies, we conducted subgroup analysis based on the sites of BMD, sample size, and age. Results showed postmenopausal women with osteoporosis had a lower concentration of serum Mg than the healthy controls in those studies which had more than 50 postmenopausal women with osteoporosis. This means that more studies with large sample sizes may prove the correctness of our conclusions. Another subgroup analysis conducted by sample size showed serum Mg levels were lower in osteoporosis than in the normal group, regardless of whether the femur or the spine were measured. A meta-analysis reported there were no significant correlations observed between Mg intake and BMD in the lumber spine (). In general, the main source of Mg is daily intake, Mg dietary deficiency can cause a decrease in the concentration of serum Mg and a loss of systemic bone mass (). So, the correlations observed of BMD in spine with serum Mg and Mg intake were difference. This may be related to the transformation and storage of Mg. We also tried to do a subgroup analysis by age, there was no correlations of serum Mg in postmenopausal women over 60 years old with osteoporosis and the healthy controls, postmenopausal women under the age of 60 with osteoporosis had a lower concentration of serum Mg than the healthy controls.
Our results showed that postmenopausal women with osteoporosis had a lower concentration of serum Mg than healthy controls but found no significant correlation between osteopenia and healthy controls. Although we combined the concentration of serum Mg between postmenopausal women with osteopenia and healthy controls and attempted to perform subgroup analysis by age and region, the results were inconclusive.
Serum Mg concentration is a useful and easily measured measure of magnesium in bone. However, in chronic latent magnesium deficiency, blood magnesium levels may remain normal despite significant reductions in tissue and bone magnesium levels. Using blood magnesium levels to determine total magnesium levels may underestimate magnesium deficiency in healthy and ill people (). This is consistent with the underestimation of the relationship between serum Mg concentration and osteoporosis that we obtained by building a trim-and-fill funnel plot. Serum Mg levels are only measured once, its correlation with osteoporosis after menopause just reflects the relationship between the two at the time, will not be able to accurately evaluate the extent of the past or the future osteoporosis. But this does not mean that the study of serum magnesium is meaningless. Through linear regression analysis, Akizawa et al. () calculated that the correlation coefficient between Japanese daily Mg intake and serum Mg concentration was 0.29 and suggested to calculate the Mg intake through serum Mg concentration to ensure the optimal individual serum magnesium concentration. By adjusting the Mg intake, the optimal serum Mg level in the human body is maintained to achieve the purpose of preventing related diseases (). Besides, our meta-analysis found the relationship between serum magnesium levels and post-osteoporosis, providing a basis for future prospective studies to verify the relationship between serum magnesium levels and osteoporosis or BMD.
Strengths and Limitations
To our knowledge, this is the first meta-analysis to explore the relationship between serum magnesium in postmenopausal women with osteoporosis, osteopenia, and normal. In the studies selected for the meta-analysis, 2,776 postmenopausal women are represented. We performed a subgroup analysis based on region, sites of BMD and sample size.
However, some limitations of our study must be considered. Firstly, the sample sizes of these studies varied significantly, which would increase heterogeneity. In contrast, the women in the included studies could be from the same place or hospital resulting in reduced heterogeneity. In order to measure heterogeneity, we conducted subgroup analysis and found that region, the sample sizes and age may be important reasons for the high heterogeneity of our studies. However, we cannot fully eliminate heterogeneity because of the diversity of studies. Secondly, only two studies mentioned adjustment of confounding variables, like age, body mass index, etc. (, ). This makes it difficult to exclude the influence of other confounders in the study which may have resulted in a bias in our analysis. Additionally, there are so few studies looking at the relationship between serum Mg and osteopenia that the amount of data we collected is very limited and our study may be underpowered. Finally, the studies that we included could be influenced by demographic characteristics, serological limitations, and other factors. Because of these reasons, we recommend that our conclusions are viewed conservatively.
Statements
Data availability statement
Publicly available datasets were analyzed in this study. This data can be found in PubMed and CnKI.
Author contributions
BY and DY designed the meta-analysis. DY, JJ, and NW performed the literature retrieval and the data extraction. JC and SY contributed the article writing. All authors read and approved the final manuscript.
Funding
This work was financially supported through grants from the Natural Science Foundation of Shandong Province (ZR2016HM43), the Medical and Health Science and Technology Development Project of Shandong Province (2016WS0582), the Clinical Medical Science and Technology Innovation Program of the Jinan Science and Technology Bureau (201602303), and the grant from the Traditional Chinese Medicine Technology Development Plan of Shandong Province (2019-0154).
Acknowledgments
We would like to thank Editage (www.editage.cn) for English language editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
FengXMcDonaldJM. Disorders of bone remodeling. Annu Rev Pathol. (2011) 6:121–45. 10.1146/annurev-pathol-011110-130203
2.
Consensus development conference: diagnosis prophylaxis and treatment of osteoporosis. Am J Med. (1993) 94:646–50. 10.1016/0002-9343(93)90218-E
3.
NIH consensus development panel on osteoporosis prevention diagnosis and therapy March 7-29 2000: highlights of the conference. South Med J. (2001) 94:569–73. 10.1097/00007611-200106000-00005
4.
CosmanFde BeurSJLeBoffMSLewieckiEMTannerBRandallSet al. Erratum to: clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. (2015) 26:2045–7. 10.1007/s00198-015-3037-x
5.
KaraguzelGHolickMF. Diagnosis and treatment of osteopenia. Rev Endocr Metab Disord. (2010) 11:237–51. 10.1007/s11154-010-9154-0
6.
MutluMArgunMKilicESaraymenRYazarS. Magnesium, zinc and copper status in osteoporotic, osteopenic and normal post-menopausal women. J Int Med Res. (2007) 35:692–5. 10.1177/147323000703500514
7.
KanisJACooperCRizzoliRReginsterJYon behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. (2019) 30:3–44. 10.1007/s00198-020-05303-5
8.
GürAColpanLNasKCevikRSaracJErdoganFet al. The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin. J Bone Miner Metab. (2002) 20:39–43. 10.1007/s774-002-8445-y
9.
CastiglioniSCazzanigaAAlbisettiWMaierJA. Magnesium and osteoporosis: current state of knowledge and future research directions. Nutrients. (2013) 5:3022–33. 10.3390/nu5083022
10.
RudeRKSingerFRGruberHE. Skeletal and hormonal effects of magnesium deficiency. J Am Coll Nutr. (2009) 28:131–41. 10.1080/07315724.2009.10719764
11.
RudeRKGruberHENortonHJWeiLYFraustoAKilburnJ. Dietary magnesium reduction to 25% of nutrient requirement disrupts bone and mineral metabolism in the rat. Bone. (2005) 37:211–19. 10.1016/j.bone.2005.04.005
12.
BoskeyALRimnacCMBansalMFedermanMLianJBoyanBD. Effect of short-term hypomagnesemia on the chemical and mechanical properties of rat bone. J Orthop Res. (1992) 10:774–83. 10.1002/jor.1100100605
13.
CarpenterTOMackowiakSJTroianoNGundbergCM. Osteocalcin and its message: relationship to bone histology in magnesium-deprived rats. Am J Physiol. (1992) 263(1 Pt 1):E107–14. 10.1152/ajpendo.1992.263.1.E107
14.
KenneyMAMcCoyHWilliamsL. Effects of magnesium deficiency on strength, mass, and composition of rat femur. Calcif Tissue Int. (1994) 54:44–49. 10.1007/BF00316289
15.
TuSJWangSPChengFCWengCEHuangWTChangWJet al. Attenuating trabecular morphology associated with low magnesium diet evaluated using micro computed tomography. PLoS ONE. (2017) 12:e0174806. 10.1371/journal.pone.0174806
16.
WuLFeyerabendFSchillingAFWillumeit-RömerRLuthringerBJC. Effects of extracellular magnesium extract on the proliferation and differentiation of human osteoblasts and osteoclasts in coculture. Acta Biomater. (2015) 27:294–304. 10.1016/j.actbio.2015.08.042
17.
RonksleyPEBrienSETurnerBJMukamalKJGhaliWA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. (2011) 342:d671. 10.1136/bmj.d671
18.
HigginsJPThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. 10.1136/bmj.327.7414.557
19.
HigginsJThompsonSG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. 10.1002/sim.1186
20.
BeggCBMazumdarM. Operating characteristics of a rank correlation test for publication bias. Biometrics. (1994) 50:1088–101. 10.2307/2533446
21.
EggerMDavey SmithGSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. 10.1136/bmj.315.7109.629
22.
DuvalSTweedieR. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. (2000) 56:455–63. 10.1111/j.0006-341X.2000.00455.x
23.
RazmandehRNasli-EsfahaniEHeydarpourRFaridbodFGanjaliMRNorouziPet al. Association of zinc, copper and magnesium with bone mineral density in Iranian postmenopausal women -a case control study. J Diabetes Metab Disord. (2014) 13:43. 10.1186/2251-6581-13-43
24.
WangSLinSZhouY. Changes of total content of serum magnesium in elderly Chinese women with osteoporosis. Biol Trace Elem Res. (2006) 110:223–31. 10.1385/BTER:110:3:223
25.
ReginsterJYStrauseLDeroisyRLecartMPSaltmanPFranchimontPet al. Preliminary report of decreased serum magnesium in postmenopausal osteoporosis. Magnesium. (1989) 8:106–9.
26.
OkyayEErtugrulCAcarBSismanAROnvuralBOzaksoyD. Comparative evaluation of serum levels of main minerals and postmenopausal osteoporosis. Maturitas. (2013) 76:320–25. 10.1016/j.maturitas.2013.07.015
27.
LiuSZYanHXuPLiJPZhuangGHZhuBFet al. Correlation analysis between bone mineral density and serum element contents of postmenopausal women in Xi'an urban area. Biol Trace Elem Res. (2009) 131:205–14. 10.1007/s12011-009-8363-4
28.
HalilogluBAksungarFBIlterEPekerHAkinTFMutluNet al. Relationship between bone mineral density, bone turnover markers and homocysteine, folate and vitamin B12 levels in postmenopausal women. Arch Gynecol Obstet. (2010) 281:663–8. 10.1007/s00404-009-1297-4
29.
JinyuChenZhengyanSLiYLinC. The relationship between serum magnesium level and bone mineral density in postmenopausal Chinese women. Chin J Osteoporos. (2007) 13:837–9.
30.
BahtiriEIslamiHRexhepiSQorraj-BytyqiHThaçiKThaçiSet al. Relationship of homocysteine levels with lumbar spine and femur neck BMD in postmenopausal women. Acta Reumatol Port. (2015) 40:355–62.
31.
MederleOABalasMIoanoviciuSDGurbanCVTudorABorzaC. Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis. Clin Interv Aging. (2018) 13:1383–9. 10.2147/CIA.S170111
32.
CunninghamJRodríguezMMessaP. Magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients. Clin Kidney J. (2012) 5(Suppl. 1):i39–51. 10.1093/ndtplus/sfr166
33.
KleinGLHerndonDN. Magnesium deficit in major burns: role in hypoparathyroidism and end-organ parathyroid hormone resistance. Magnes Res. (1998) 11:103–9.
34.
RudeRKAdamsJSRyzenEEndresDBNiimiRHorstRLet al. Low serum concentrations of 1,25-dihydroxyvitamin D in human magnesium deficiency. J Clin Endocrinol Metab. (1985) 61:933–40. 10.1210/jcem-61-5-933
35.
BurgeRDawson-HughesBSolomonDHWongJBKingATostesonA. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. (2007) 22:465–75. 10.1359/jbmr.061113
36.
CreedonAFlynnACashmanK. The effect of moderately and severely restricted dietary magnesium intakes on bone composition and bone metabolism in the rat. Br J Nutr. (1999) 82:63–71. 10.1017/S0007114599001130
37.
LeidiMDelleraFMariottiMBanfiGCrapanzanoCAlbisettiWet al. Nitric oxide mediates low magnesium inhibition of osteoblast-like cell proliferation. J Nutr Biochem. (2012) 23:1224–9. 10.1016/j.jnutbio.2011.06.016
38.
BelluciMMSchoenmakerTRossa-JuniorCOrricoSRde VriesTJEvertsV. Magnesium deficiency results in an increased formation of osteoclasts. J Nutr Biochem. (2013) 24:1488–98. 10.1016/j.jnutbio.2012.12.008
39.
AyukJGittoesNJ. Contemporary view of the clinical relevance of magnesium homeostasis. Ann Clin Biochem. (2014) 51(Pt 2):179–88. 10.1177/0004563213517628
40.
RazzaqueMS. Magnesium: are we consuming enough?Nutrients. (2018) 10:1863. 10.3390/nu10121863
41.
Farsinejad-MarjMSaneeiPEsmaillzadehA. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int. (2016) 27:1389–99. 10.1007/s00198-015-3400-y
42.
BelluciMMGiroGDel BarrioRALPereiraRMRMarcantonioEJrOrricoSRP. Effects of magnesium intake deficiency on bone metabolism and bone tissue around osseointegrated implants. Clin Oral Implants Res. (2011) 22:716–21. 10.1111/j.1600-0501.2010.02046.x
43.
AkizawaYKoizumiSItokawaYOjimaTNakamuraYTamuraTet al. Daily magnesium intake and serum magnesium concentration among Japanese people. J Epidemiol. (2008) 18:151–9. 10.2188/jea.JE2007381
Summary
Keywords
serum magnesium, postmenopausal, osteoporosis, osteopenia, meta-analysis
Citation
Chang J, Yu D, Ji J, Wang N, Yu S and Yu B (2020) The Association Between the Concentration of Serum Magnesium and Postmenopausal Osteoporosis. Front. Med. 7:381. doi: 10.3389/fmed.2020.00381
Received
17 March 2020
Accepted
19 June 2020
Published
04 August 2020
Volume
7 - 2020
Edited by
Tzvi Dwolatzky, Technion Israel Institute of Technology, Israel
Reviewed by
Vahidreza Ostadmohammadi, Kashan University of Medical Sciences, Iran; Liang-Yu Chen, Taipei Veterans General Hospital, Taiwan
Updates
Copyright
© 2020 Chang, Yu, Ji, Wang, Yu and Yu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bo Yu ybshengzhongyi@126.com
This article was submitted to Geriatric Medicine, a section of the journal Frontiers in Medicine
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.